Sesame, the ninth most common allergen in the U.S, will now be subject to the same labeling and manufacturing requirements as other major food allergens, such as milk, shellfish and peanuts.
was signed into law in April 2021 and expanded the definition of “major food allergen” to include sesame.
Food already in circulation before 2023 doesn’t need to be removed from retail shelves or relabeled to declare sesame an allergen — “so depending on shelf life, some food products may not have allergen labeling for sesame on the effective date,” the FDA said.
Dr. Scott H. Sicherer, one of the authors of the study and director of the Jaffe Food Allergy Institute at Mount Sinai, said in an email to Yahoo News that other countries such as Canada and Australia, and the European Union, have included sesame in their labeling laws for years “and, happily, now the US laws also include sesame.”
“For our patients, going forward this means that sesame cannot be hidden in umbrella terms such as ‘natural flavoring’ or ‘spices’ and people will not have to make a mistake because a word like ‘tahini’ is on a label but not the word ‘sesame,’” Sicherer said.— from baked goods and bread crumbs to sushi, soups, dressings and sauces.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Sesame joins the major food allergens list, FDA saysSesame has joined the list of major food allergens defined by law, according to the U.S. Food and Drug Administration.
Baca lebih lajut »
Sesame added to major food allergens list by FDAAs of Jan. 1, sesame has officially joined the list of major food allergens, the U.S. Food and Drug Administration said.
Baca lebih lajut »
New law requires sesame allergy warning on food labelsA new law requires sesame allergy warnings on food labels. We hear from an advocate about why the change will impact about one million Americans.
Baca lebih lajut »
House investigation finds FDA, drug firm Biogen ignored internal concerns for Alzheimer's drugA congressional investigation into the FDA's review process for an Alzheimer's treatment found that the agency 'deviated' from its standard procedures to approve the Aduhelm drug with inconsistent data.
Baca lebih lajut »
FDA decision on experimental Alzheimer's drug expected this week | CNNThe US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental Alzheimer's drug lecanemab, according to Eisai and Biogen, the companies that make the drug.
Baca lebih lajut »
Controversial Alzheimer's drug, explained: What to know about Aduhelm, FDA and scathing reportThe FDA's approval process of Alzheimer’s drug Aduhelm has been deemed “rife with irregularities,” according to a congressional investigation. Here are takeaways from the report.
Baca lebih lajut »